🤔
Shares of nano-cap diagnostics company Virax Biolabs Group (NASDAQ:VRAX) more than doubled in value in the morning hours Thursday as the company drew Wall Street's attention amid a rising number of bird flu cases worldwide.
Several countries, including the U.S., have already reported human bird flu infections as the highly pathogenic avian influenza virus, including its H5N1 form, continues to spread in poultry and cattle.
Several countries, including the U.S., have already reported human bird flu infections as the highly pathogenic avian influenza virus, including its H5N1 form, continues to spread in poultry and cattle.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
We rise together.
10+ years of momentum and swing trading.
Options trader since 2020.
645Followers
10Following
4727Visitors
Follow
MIKE25y : What does it matter...
QuintusChen MIKE25y : In March 2023, Virax launched it's avian influenza A virus real-time PCR test kit in the European Union for laboratory use. The test can detect and differentiate H5, H7, and H9 subtypes, including the H5N1 strain of the virus, the U.K.-based firm said at the time.
MIKE25y QuintusChen : This company doesn't have any revenue from this; your benefits are just false to them